Neoadjuvant endocrine therapy (NET) is a treatment option for postmenopausal patients with hormone receptor-positive (HR+)/HER2-negative early breast cancer, aimed at shrinking tumors before surgery. The gene discussed is NR4A1; the disease is breast cancer.